Valeant Completes $2.25 Billion Acquisition Financing
Cahill represented the initial purchasers in connection with the Rule 144A/Reg S offering of $1,750,000,000 6.375% Senior Notes due 2020 for VPI Escrow Corp., the proceeds of which will be used to partially finance the acquisition of drug maker Medicis Pharmaceutical Corporation. The obligations of VPI Escrow Corp. under the notes will be assumed by Valeant Pharmaceuticals International upon the consummation of Valeant’s acquisition of Medicis. Cahill also represented the initial purchasers in connection with the concurrent Rule 144A/Reg S offering of $500,000,000 6.375% Senior Notes due 2020 by Valeant Pharmaceuticals International. Proceeds from this offering will be used for general corporate purposes by Valeant, including certain acquisitions.